Gradual Dose Reduction Without Abrupt Cessation
When discontinuing oral isosorbide dinitrate, gradually reduce the dose rather than stopping abruptly to avoid potential rebound ischemia, though specific tapering schedules are not established in guidelines. 1
Key Principles for Discontinuation
Avoid Abrupt Cessation
The ACC/AHA guidelines explicitly warn that abrupt cessation of intravenous nitroglycerin has been associated with exacerbation of ischemic changes on the ECG, and a graded reduction in dose is advisable 1. While this recommendation specifically addresses IV nitroglycerin, the same principle applies to oral nitrates given the risk of rebound phenomena.
Evidence of Rebound Risk
- Industrial workers with long-term nitrate exposure have experienced chest pain, acute MI, and even sudden death during temporary withdrawal, demonstrating true physical dependence 2
- In clinical trials, some patients experienced increased frequency of anginal attacks during nitrate-free intervals 1
- However, one study of isosorbide-5-mononitrate withdrawal found that 3 of 32 patients required hospitalization due to sudden symptom deterioration 3
Practical Tapering Approach
Suggested Strategy
While no standardized tapering protocol exists in guidelines, a reasonable approach based on available evidence includes:
For patients on regular dosing (e.g., 40 mg twice daily):
- Reduce to once-daily dosing for 1-2 weeks
- Then reduce to 20 mg once daily for 1-2 weeks
- Then discontinue
For patients on higher doses (e.g., 80 mg twice daily):
- Reduce by 50% of each dose for 1-2 weeks
- Continue stepwise reductions every 1-2 weeks
- Monitor closely for recurrent angina
Critical Monitoring Points
- Assess for recurrent chest pain or anginal symptoms during each reduction
- Ensure patients have sublingual nitroglycerin available for breakthrough symptoms
- Consider slower tapering in patients with:
- History of unstable angina
- Recent acute coronary syndrome
- Severe coronary disease
- Previous withdrawal symptoms
Important Caveats
When Tapering May Not Be Necessary
The FDA label for isosorbide dinitrate 4 does not mandate tapering, and one study showed that once-daily isosorbide-5-mononitrate could be withdrawn without deterioration in most patients 3. However, the risk of rebound in susceptible individuals justifies a cautious approach.
Tolerance Considerations
Patients on continuous dosing regimens (three or four times daily) may have developed tolerance 5, 6, 7, potentially reducing withdrawal risk. Paradoxically, those on appropriate intermittent regimens (once or twice daily with nitrate-free intervals) who maintain efficacy may be at higher risk for rebound.
Alternative to Complete Discontinuation
If discontinuation is for tolerance management rather than medication cessation, consider switching to an intermittent dosing regimen with a 14-hour nitrate-free interval rather than stopping entirely 4, 1.